3,4-Dihydroxybenzylamine hydrobromide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

3,4-二羟基苯甲胺氢溴酸盐抑制黑色素瘤细胞中的 DNA 聚合酶活性，并在具有不同程度酪氨酸酶活性的黑色素瘤细胞系中表现出生长抑制活性。

3,4-Dihydroxybenzylamine hydrobromide inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.(In Vitro):3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines (IC50 = 100 μM) and the SK-MELB cell line (IC50 = 122 μM). The IC50 values are 30, 84,90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3,RPMI-7951 cells, respectively. 3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3,4-DHBA, and the presence of decreses IC50 values of 3,4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line. 3,4-Dihydroxybenzylamine hydrobromide exhibits IC50values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells, respectively.(In Vivo):3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose.

3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines with an IC50 of 100 μM, while the SK-MELB cell line exhibits an IC50 of 122 μM. The IC50 values are 30, 84,90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3,RPMI-7951 cells, respectively. It exhibits IC50values of 10, 25, 67, and 184 μM for S91A,S91B,L1210, and SCC-25 cells, respectively.3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3,4-DHBA, and the presence of decreses IC50 values of 3,4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line. Cell Viability Assay Cell Line:Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines Concentration:1 μM-10 mM Incubation Time:48 hours Result:Inhibited melanoma cell Lines growth.

3,4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 1000 mg/kg; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose.3,4-Dihydroxybenzylamine hydrobromide (intraperitoneal injection; 200-800 mg/kg; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days for 0 mg/kg, 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively. Animal Model:C57BL/6 mice withB6D2F1 cells Dosage:200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg Administration:Intraperitoneal injection Result:Exhibited increased life-span of 44%,46%, 70% and 50% for 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg, respectively.

NSC 263475 hydrobromide

Others

Other Targets

P450| protein tyrosine phosphatase(PTP)| SETD8

——

——

16290-26-9

220.066

C7H10BrNO2

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (378.67 mM)

Br.NCc1ccc(O)c(O)c1

——

(-20℃)

With Ice Pack

≥ 2 years